Selvita - your integrated drug discovery partner of choice

The largest drug
discovery company
in the CEE region

Your integrated drug
discovery partner of choice

Developing breakthrough
therapies in oncology

Delivering comprehensive
research solutions to biotech
and pharma

- Both companies will be independently listed on the Warsaw Stock Exchange with formal completion of the split expected in...

Krakow, Poland – 06 September 2019 – Selvita (WSE: SLV) today announced that the first patient enrolled in the Phase...

Krakow, Poland – 5 September 2019 – Selvita (WSE:SLV) today reported second quarter 2019 financial results and provided a corporate...

- Shareholder meeting to be held Sept. 19, 2019, for a vote on the split, name of Ryvu Therapeutics for...

Krakow, Poland – 3 September 2019 – Selvita (WSE: SLV) today announced that Pawel Przewiezlikowski, Chief Executive Officer, will present...

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

In its internal research and development efforts, Selvita focuses on different dimensions of oncology.

The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.

60,2000 PLN More

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.